Supplylogix inks deal with Midwest healthcare provider
GRAPEVINE, Texas — Healthcare technology company Supplylogix has signed an agreement with an unnamed healthcare provider in the Midwest to provide pharmaceutical inventory management and demand forecasting.
Supplylogix will provide the services for the provider’s 80 pharmacies and central-fill facility, and the provider recently completed a 45-day full deployment of the company’s services.
“Our ability to offer the level of control our clients require to manage pharmaceutical inventory, as well as optimize for specific demand as prescriptions shift between community pharmacies and central fill, was key to earning this business,” Supplylogix president and CEO Mark Wilgus said. “This client is a widely respected provider of health care within their communities, and we look forward to helping them serve their pharmacy patients and drive new efficiencies in their pharmacy operations.”
BioPlus leader offers information, commentary via Dr. Vogt’s BioBlog
ALTAMONTE SPRINGS, Fla. — As a relatively new facet of the pharmacy profession, specialty pharmacy is constantly developing, prompting the leader of one provider to go online to keep patients and physicians up to date.
BioPlus Specialty Pharmacy president and CEO Stephen Vogt has launched Dr. Vogt’s BioBlog, providing commentary and information to patients and physicians about developments in specialty pharmacy. Vogt will post weekly updates with his perspective and experience about current advancements and events in specialty pharmacy related to such chronic illnesses as hepatitis, cancer, rheumatoid arthritis and others.
“Dr. Vogt’s experience, knowledge and skill in this area give him a unique perspective on new developments in our field,” BioPlus director of pharmacy services Nick Maroulis said. “For example, instead of just hearing about a new drug being released, readers of Dr. Vogt’s BioBlog will get an understanding of what the new drug will mean to their lives and disease treatment.”
The blog can be accessed at BioPlusSP.com.
Takeda resubmits new drug applications for Type 2 diabetes treatments
OSAKA, Japan — Japanese drug maker Takeda Pharmaceutical is reapplying for approval of two drugs to treat Type 2 diabetes after the Food and Drug Administration turned down its last applications, the company said.
Takeda announced that it resubmitted its applications for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in Actos, which the FDA approved in 1999.
The FDA will review the applications over the next six months, the drug maker said.